Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome?

Hamdan Hamdan; Shahrukh K. Hashmi; Hillard Lazarus; Robert Peter Gale; Wenchun Qu; Riad El Fakih

doi:10.1016/j.blre.2020.100742

Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome?

Hamdan Hamdan, Shahrukh K. Hashmi, Hillard Lazarus, Robert Peter Gale, Wenchun Qu, Riad El Fakih

Physical Medicine and Rehabilitation

Research output: Contribution to journal › Review article › peer-review

Abstract

Mesenchymal stromal cells (MSC) have immune regulatory and tissue regenerative properties. MSCs are being studied as a therapy option for many inflammatory and immune disorders and are approved to treat acute graft-versus-host disease (GvHD). The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic and associated coronavirus infectious disease-19 (COVID-19) has claimed many lives. Innovative therapies are needed. Preliminary data using MSCs in the setting of acute respiratory distress syndrome (ARDS) in COVID-19 are emerging. We review mechanisms of action of MSCs in inflammatory and immune conditions and discuss a potential role in persons with COVID-19.

Original language	English (US)
Article number	100742
Journal	Blood Reviews
Volume	46
DOIs	https://doi.org/10.1016/j.blre.2020.100742
State	Published - Mar 2021

Keywords

COVID-19
Mesenchymal stromal cell
SARS-CoV2

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.blre.2020.100742

Cite this

@article{20658a7242304f8f84ef23c432964855,

title = "Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome?",

abstract = "Mesenchymal stromal cells (MSC) have immune regulatory and tissue regenerative properties. MSCs are being studied as a therapy option for many inflammatory and immune disorders and are approved to treat acute graft-versus-host disease (GvHD). The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic and associated coronavirus infectious disease-19 (COVID-19) has claimed many lives. Innovative therapies are needed. Preliminary data using MSCs in the setting of acute respiratory distress syndrome (ARDS) in COVID-19 are emerging. We review mechanisms of action of MSCs in inflammatory and immune conditions and discuss a potential role in persons with COVID-19.",

keywords = "COVID-19, Mesenchymal stromal cell, SARS-CoV2",

author = "Hamdan Hamdan and Hashmi, {Shahrukh K.} and Hillard Lazarus and Gale, {Robert Peter} and Wenchun Qu and {El Fakih}, Riad",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Ltd",

year = "2021",

month = mar,

doi = "10.1016/j.blre.2020.100742",

language = "English (US)",

volume = "46",

journal = "Blood Reviews",